The BIN3 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the BIN3 gene in the HT29 human colorectal adenocarcinoma cell line. This loss-of-function model enables investigation of BIN3-dependent processes without clonal selection, providing a heterogeneous yet functionally relevant system for studying gene function in a colorectal cancer context. The polyclonal format retains cellular diversity while ensuring robust target-gene disruption, making it suitable for functional genomics, drug discovery, and mechanistic studies.
The host HT29 cell line, derived from a 44-year-old female with colorectal adenocarcinoma, is a widely characterized epithelial model with microsatellite stability (MSS), BRAF V600E mutation, TP53 mutation, and MLH1 hypermethylation. These cells are extensively employed in intestinal barrier function research, differentiation studies, and colorectal cancer biology. Their well-defined genetic background, including aberrant MAPK and p53 signaling, provides a clinically relevant platform for dissecting tumorigenic mechanisms and evaluating therapeutic responses.
BIN3 encodes a BAR domain-containing protein that facilitates membrane curvature and endocytosis, interacting directly with DYNLT1, actin, and dynamin to modulate vesicle trafficking and cytoskeletal organization. It functions within a network involving clathrin-mediated endocytosis, the ARP2/3 complex, and RAC1-dependent actin dynamics, positioning it at the intersection of membrane remodeling and signal transduction. BIN3 has been implicated in cell division and apoptosis, and its disruption may alter the trafficking of growth factor receptors and adhesion molecules, thereby affecting downstream pathways such as MAPK/ERK and cell cycle progression.
In the HT29 adenocarcinoma context, BIN3 knockout is expected to perturb endocytic pathways and actin cytoskeleton dynamics, potentially impacting cell proliferation, apoptosis, and tumorigenic signaling. The presence of BRAF V600E and TP53 mutations in HT29 cells creates a specific oncogenic environment where BIN3 loss may synergize with or counteract established driver mutations, offering insights into compensatory mechanisms or tumor-suppressive functions. This model is thus valuable for elucidating how membrane trafficking disturbances contribute to colorectal cancer pathogenesis.
Typical research applications include colorectal cancer research, endocytosis and membrane trafficking studies, tumor suppressor function investigation, drug sensitivity screening, migration and invasion assays, and apoptosis studies. Representative assays such as Western blotting, RT-qPCR, RNA-seq, immunofluorescence, flow cytometry, Transwell migration/invasion, drug sensitivity assays, and co-immunoprecipitation are well-suited to characterize the knockout phenotype. For additional details, please contact Ascent Research.
